Biosimilar Application Pathway Likely To Travel Through Courts
Executive Summary
The courts likely will get involved in biosimilars even if FDA decides which application pathway a biosimilar would travel, a consultant and former FDA official said.
You may also be interested in...
Biosimilars: After FDA's Public Meeting, Is A Payer Summit Needed Too?
FDA may be forced to campaign for support of its biosimilar decisions in the health care community to ensure entities like hospital Pharmacy and Therapeutics Committees embrace the products.
Biosimilars: After FDA's Public Meeting, Is A Payer Summit Needed Too?
FDA may be forced to campaign for support of its biosimilar decisions in the health care community to ensure entities like hospital Pharmacy and Therapeutics Committees embrace the products.
Waxman Says Biosimilar Pathway Will Push Applicants To BLA
The outgoing chairman of the House Energy and Commerce Committee said the new abbreviated biosimilar pathway FDA is now formulating likely will not attract many applicants.